未来治疗Fuchs内皮性角膜营养不良的有效方法展望。

IF 0.4 Q4 OPHTHALMOLOGY Open Ophthalmology Journal Pub Date : 2018-07-23 eCollection Date: 2018-01-01 DOI:10.2174/1874364101812010154

Naoki Okumura, Ryousuke Hayashi, Noriko Koizumi

{"title":"未来治疗Fuchs内皮性角膜营养不良的有效方法展望。","authors":"Naoki Okumura, Ryousuke Hayashi, Noriko Koizumi","doi":"10.2174/1874364101812010154","DOIUrl":null,"url":null,"abstract":"Background: Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive disease that affects the corneal endothelium in both eyes. Recent studies have identified a novel genetic basis for FECD, and basic research findings have provided evidence for its underlying pathophysiology. Since its first description by Ernst Fuchs in 1910, the only therapeutic choice has been corneal transplantation using donor corneas. However, accumulating evidence suggests that a change in this \"rule\" may be imminent.Conclusions: This article reviews the current knowledge of the genetics and pathophysiology of FECD, and it introduces some potent therapeutic modalities that show promise as new treatments for this disorder.","PeriodicalId":46347,"journal":{"name":"Open Ophthalmology Journal","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2018-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062905/pdf/","citationCount":"7","resultStr":"{\"title\":\"Perspective of Future Potent Therapies for Fuchs Endothelial Corneal Dystrophy.\",\"authors\":\"Naoki Okumura, Ryousuke Hayashi, Noriko Koizumi\",\"doi\":\"10.2174/1874364101812010154\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive disease that affects the corneal endothelium in both eyes. Recent studies have identified a novel genetic basis for FECD, and basic research findings have provided evidence for its underlying pathophysiology. Since its first description by Ernst Fuchs in 1910, the only therapeutic choice has been corneal transplantation using donor corneas. However, accumulating evidence suggests that a change in this \\\"rule\\\" may be imminent.Conclusions: This article reviews the current knowledge of the genetics and pathophysiology of FECD, and it introduces some potent therapeutic modalities that show promise as new treatments for this disorder.\",\"PeriodicalId\":46347,\"journal\":{\"name\":\"Open Ophthalmology Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2018-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062905/pdf/\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Ophthalmology Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1874364101812010154\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Ophthalmology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874364101812010154","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 7

摘要

背景:Fuchs内皮性角膜营养不良(FECD)是一种累及双眼角膜内皮的进行性疾病。最近的研究已经确定了FECD的新的遗传基础，基础研究结果为其潜在的病理生理提供了证据。自1910年Ernst Fuchs首次描述以来，唯一的治疗选择是使用供体角膜进行角膜移植。然而，越来越多的证据表明，这一“规则”可能即将发生变化。结论:本文综述了FECD的遗传学和病理生理学的现有知识，并介绍了一些有效的治疗方法，有望成为这种疾病的新治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Perspective of Future Potent Therapies for Fuchs Endothelial Corneal Dystrophy.

Background: Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive disease that affects the corneal endothelium in both eyes. Recent studies have identified a novel genetic basis for FECD, and basic research findings have provided evidence for its underlying pathophysiology. Since its first description by Ernst Fuchs in 1910, the only therapeutic choice has been corneal transplantation using donor corneas. However, accumulating evidence suggests that a change in this "rule" may be imminent.

Conclusions: This article reviews the current knowledge of the genetics and pathophysiology of FECD, and it introduces some potent therapeutic modalities that show promise as new treatments for this disorder.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Open Ophthalmology Journal OPHTHALMOLOGY-

CiteScore

0.50

自引率

0.00%

发文量

期刊介绍： The Open Ophthalmology Journal is an Open Access online journal, which publishes research articles, reviews/mini-reviews, letters and guest edited single topic issues in all important areas of experimental and clinical research in ophthalmology, including use of ophthalmological therapies, devices and surgical techniques. The Open Ophthalmology Journal, a peer-reviewed journal, is an important and reliable source of current information on developments in the field. The emphasis will be on publishing quality papers rapidly and making them freely available to researchers worldwide.